MUC1 介导的乳腺癌免疫治疗进展。
Advances in MUC1-Mediated Breast Cancer Immunotherapy.
机构信息
Medical School of Nantong University, Nantong 226019, China.
Research Center of Clinical Medicine, Jiangsu Taizhou People's Hospital (Affiliated Hospital 5 of Nantong University), Taizhou 225300, China.
出版信息
Biomolecules. 2022 Jul 6;12(7):952. doi: 10.3390/biom12070952.
Breast cancer (BRCA) is the leading cause of death from malignant tumors among women. Fortunately, however, immunotherapy has recently become a prospective BRCA treatment with encouraging achievements and mild safety profiles. Since the overexpression and aberrant glycosylation of MUC1 (human mucin) are closely associated with BRCA, it has become an ideal target for BRCA immunotherapies. In this review, the structure and function of MUC1 are briefly introduced, and the main research achievements in different kinds of MUC1-mediated BRCA immunotherapy are highlighted, from the laboratory to the clinic. Afterward, the future directions of MUC1-mediated BRCA immunotherapy are predicted, addressing, for example, urgent issues in regard to how efficient immunotherapeutic strategies can be generated.
乳腺癌（BRCA）是女性恶性肿瘤死亡的主要原因。然而，幸运的是，免疫疗法最近已成为一种有前景的 BRCA 治疗方法，取得了令人鼓舞的成果，且安全性良好。由于 MUC1（人粘蛋白）的过度表达和异常糖基化与 BRCA 密切相关，因此它已成为 BRCA 免疫疗法的理想靶标。在这篇综述中，简要介绍了 MUC1 的结构和功能，并重点介绍了不同类型的 MUC1 介导的 BRCA 免疫疗法从实验室到临床的主要研究成果。随后，预测了 MUC1 介导的 BRCA 免疫疗法的未来方向，例如，如何生成有效的免疫治疗策略等问题。
Zotero 插件